Shares of Orexigen Therapeutics Inc. (Nasdaq: OREX) climbed again by gaining 84 cents to $5.76 after rival Arena Pharmaceuticals Inc.'s (Nasdaq: ARNA) weight loss treatment Lorcaserin was approved yesterday. Arena stock dropped $1.29 to $10.10 as investors locked in profits on the biopharmaceutical.